Valeant Pharmaceuticals on Friday filed its long-overdue U.S. financial report for 2015, plus restated results for several quarters, resolving its default on some of its $30 billion in debt and averting other problems. The badly tarnished Canadian drugmaker also announced a slate of mostly new nominees for elections to its board in June.
Valeant files overdue financial report, ending debt default
Aucun commentaire:
Enregistrer un commentaire